Jane Street’s Nuvectis Pharma NVCT Stock Holding History

Jane Street’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-26,278	Closed	-$171K	–	11978
2025 Q3	$158K	Buy	+26,278	New	+$181K	﹤0.01%	9849
2025 Q2	–	Sell	-42,299	Closed	-$413K	–	10479
2025 Q1	$413K	Buy	+42,299	New	+$305K	﹤0.01%	7220
2024 Q3	–	Sell	-17,021	Closed	-$108K	–	10146
2024 Q2	$108K	Buy	+17,021	New	+$116K	﹤0.01%	8700
2023 Q2	–	Sell	-11,086	Closed	-$145K	–	9291
2023 Q1	$145K	Buy	+11,086	New	+$112K	﹤0.01%	8030

Other funds holding NVCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street's NVCT Position: Q4 2025 in Review

Jane Street sold out of Nuvectis Pharma (NVCT) in Q4 2025, closing a stake of 26,278 shares — an estimated $171K sold.

Jane Street first reported a position in NVCT in Q1 2023 and held it in 4 quarters. The position peaked at $413K in Q1 2025. 48 funds tracked by Wall St. Rank hold NVCT as of Q4 2025.

Jane Street reported no remaining Nuvectis Pharma position as of Q4 2025 after selling out during the quarter.
Jane Street sold 26,278 Nuvectis Pharma shares in Q4 2025, an estimated $171K.
Jane Street first reported a position in Nuvectis Pharma in Q1 2023 and held it in 4 quarters.
Jane Street's Nuvectis Pharma position peaked at $413K in Q1 2025.
48 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.